Evidence map›Paper›PMID 42783209›Full record

ReviewDiseases (Basel, Switzerland)2026

Safety and Effectiveness of Probiotic Preparations: A Contemporary Review.

Erik Shorabaev, Amankeldi Sadanov, Baiken Baimakhanova, Irina Ratnikova, Gulzakira Xetayeva, Sholpan Akhelova, Aknur Turgumbayeva

Abstract readReview
In one paragraph

Review in Diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Erik ShorabaevResearch and Production Center for Microbiology and Virology LLP, 105 Bogenbay Batyr St., Almaty 050010, Kazakhstan.
Amankeldi SadanovResearch and Production Center for Microbiology and Virology LLP, 105 Bogenbay Batyr St., Almaty 050010, Kazakhstan.
Baiken BaimakhanovaResearch and Production Center for Microbiology and Virology LLP, 105 Bogenbay Batyr St., Almaty 050010, Kazakhstan.ORCID 0000-0002-7119-950X
Irina RatnikovaResearch and Production Center for Microbiology and Virology LLP, 105 Bogenbay Batyr St., Almaty 050010, Kazakhstan.ORCID 0000-0002-7045-1865
Gulzakira XetayevaDepartment of Pediatric Infectious Diseases, S.D. Asfendiyarov Kazakh National Medical University, 94 Tole Bi St., Almaty 050012, Kazakhstan.
Sholpan AkhelovaDepartment of Pharmaceutical Disciplines, Astana Medical University, 33 Saryarka Ave., Astana 010000, Kazakhstan.
Aknur TurgumbayevaFaculty of Medicine and Health Care, Farabi University, 71 Al-Farabi Ave., Almaty 050040, Kazakhstan.

Funding

BR28712749 BR28712749
6 · The paper itself

Abstract

BACKGROUND/

objectivesProbiotic preparations have attracted increasing attention because of their potential to modulate the gut microbiota and improve health outcomes in a wide range of gastrointestinal and extraintestinal diseases. However, their efficacy and safety are strain-specific and remain inconsistent across many clinical indications. The aim of this review was to evaluate current evidence regarding the efficacy, safety, mechanisms of action, and clinical applications of probiotic preparations.

methodsA narrative literature review was conducted using the PubMed, Scopus, and Web of Science databases to identify publications addressing the efficacy, safety, and clinical applications of probiotic preparations. The literature search was last updated in July 2026. No publication-year restrictions were applied; the studies included in this review were published between 2000 and 2026. Priority was given to systematic reviews, meta-analyses, randomized controlled trials, international clinical practice guidelines, and mechanistic studies.

resultsThe reviewed evidence indicates that probiotics may contribute to intestinal homeostasis through modulation of the gut microbiota, enhancement of intestinal barrier function, and regulation of immune responses. The strongest evidence supports the use of selected probiotic strains for the prevention of antibiotic-associated diarrhea, whereas evidence for the prevention of necrotizing enterocolitis is generally favorable but depends on the specific probiotic preparation, product quality, and clinical setting. Evidence for most other gastrointestinal and extraintestinal disorders remains heterogeneous and strain-specific. Although probiotics generally exhibit a favorable safety profile, rare infectious complications have been reported in high-risk patients.

conclusionsCurrent evidence indicates that the efficacy and safety of probiotics depend on the specific strain, clinical indication, and patient characteristics. Further high-quality, strain-specific clinical studies are needed to optimize their use in medical practice.

Indexed as

antibiotic-associated diarrheaClostridioides difficile infectiongut microbiotainflammatory bowel diseaseintestinal barrierirritable bowel syndromeprobiotic preparationsprobioticsprobiotic safety

Identifiers

PMID42783209
PMCPMC13605352

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.